Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics


Unum Therapeutics has developed novel platform technologies to treat cancer with distinct advantages over other T cell therapy approaches by: 1) activating T cells specifically against tumor antigens while preventing attacks on healthy cells and 2) overcoming immunosuppression in the solid tumor microenvironment that would otherwise prevent T cells from doing their job.


Unum’s Antibody-Coupled T cell Receptor (ACTR), an autologous engineered T cell therapy, combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immune responses.


Unum’s Bolt-On Chimeric Receptor (BOXR) platform is designed to discover novel “bolt-on” transgenes to enhance intrinsic T cell functionality and overcome multiple mechanisms of immunosuppression in the solid tumor microenvironment.